Pegylated liposomal doxorubicin: Tolerability and toxicity
Pegylated liposomal doxorubicin: Tolerability and toxicity
复制标题
DOI：
10.1592/phco.21.7.751.34572
复制
发表时间：
2001-06-01
期刊：
影响因子：
4.1
通讯作者：
Richmond, PL
中科院分区：
文献类型：
--
作者：
Goram, AL;Richmond, PL
我们评估了聚乙二醇化脂质体多柔比星（PL-DOX）在复发或难治性卵巢癌妇女中的耐受性和毒性，并回顾了预防或治疗该药物引起的毒性的方法。回顾了1997年10月至2000年12月期间接受PL-DOX治疗的13名妇女的医疗记录。患者1-8在1997年加入医院处方后接受了PL-DOX治疗。9 ~ 13例患者经医务人员教育后接受。收集用药前、周期数、剂量、输注时间、耐受性、副作用和反应指标的数据。第二组PL-DOX的中位周期数和累积剂量/患者（6和420 mg）高于第一组（2和240 mg）。患者因素，如疾病持续时间和化疗周期数影响耐受性，一名患者在接受第一次剂量的几分钟内出现了危及生命的不良反应。停止治疗后，患者成功复苏。其他限制剂量或治疗的并发症（中性粒细胞减少症、口炎、跖掌红肿）均有记录。毒性管理包括减少剂量或延迟治疗；治疗经常中断。与长期患病的女性患者相比，近期患病的患者在复发早期给予更多的PL-DOX治疗周期。耐受性不一定表示反应。该药物易于使用，但其耐受性和缺乏统一的毒性管理仍然值得关注。
We evaluated the tolerability and toxicity attributed to pegylated liposomal doxorubicin (PL-DOX) in women with recurrent or refractory ovarian cancer, and reviewed procedures to prevent or treat toxicity induced by the agent. Medical records of 13 women who received PL-DOX between October 1997 and December 2000 were reviewed. Patients 1-8 received PL-DOX once it was added to the hospital formulary in 1997. Patients 9-13 received it after medical staff education. Data on premedications, number of cycles, dosage, length of infusion, tolerability, side effects, and indicators for response were collected. The median number of cycles and cumulative dose/patient of PL-DOX were higher (6 and 420 mg) in the second group than in the first group (2 and 240 mg). Patient factors such as duration of disease and number of chemotherapy cycles influenced tolerability One patient experienced a life-threatening adverse reaction within minutes of receiving the first dose. Treatment was discontinued, and she was resuscitated successfully Other dose- or treatment-limiting complications (neutropenia, stomatitis, plantar-palmar erythrodysesthesia) were documented. Toxicity management consisted of dosage reduction or treatment delay; treatment often was discontinued. Patients with recent disease tolerated more cycles of PL-DOX when given early in recurrence compared with heavily pretreated women with long-standing disease. Tolerability was not necessarily indicative of response. The agent is simple to administer, but its tolerability and lack of uniform toxicity management remain concerns.